CJC/Ipamorelin 5/5mg Spray is a research-grade synergistic peptide blend formulated in a pre-metered liquid vehicle for non-invasive laboratory research. Combining CJC-1295 No DAC (Modified GRF 1-29, GHRH agonist) and Ipamorelin (selective GHSR agonist), this dual-action solution stimulates pulsatile growth hormone secretion via complementary cellular pathways. Formulated as a stabilized solution, each bottle contains 5mg of CJC-1295 No DAC and 5mg of Ipamorelin, analytically verified by HPLC to support reproducible scientific investigations in endocrinology and mucosal transport kinetics.
HPLC certified
Independent analysis
Highest standard
Full traceability
CJC/Ipamorelin 5/5mg Spray is a synthetic peptide combination solution designed to evaluate the synergistic activation of pituitary somatotrophs. CJC-1295 No DAC acts as a GHRH receptor agonist, incorporating four stabilizing substitutions (D-Ala2, Gln8, Ala15, and Leu27) to prevent rapid enzymatic degradation. Ipamorelin is a highly selective growth hormone secretagogue receptor (GHSR) agonist pentapeptide (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that mimics ghrelin activity. Together, they stimulate growth hormone release through separate intracellular signaling networks (cAMP/PKA and PLC/IP3/intracellular calcium pathways).
Researchers continue to investigate the CJC/Ipamorelin blend across peptide pharmacology, endocrine feedback dynamics, and non-parenteral delivery systems. The combination is of high scientific interest because GHRH and GHSR agonists act synergistically—the simultaneous activation of somatotroph receptors and inhibition of hypothalamic somatostatin results in growth hormone release significantly greater than the additive effect of either peptide alone. Formulated as a liquid spray, this product provides a pre-dissolved format that bypasses reconstruction steps, serving as a valuable molecular tool for laboratories examining mucosal barrier transport and olfactory uptake kinetics.
CJC/Ipamorelin 5/5mg Spray is a research-grade synthetic peptide combination solution developed for laboratory investigations involving growth hormone regulation, dual-receptor pituitary signaling, and non-invasive delivery methods. Chemically, it combines a modified 29-amino-acid GHRH analog (CJC-1295 No DAC / Mod GRF 1-29) and a selective 5-amino-acid GH secretagogue receptor agonist (Ipamorelin). This dual-action design targets two distinct receptor populations on anterior pituitary somatotrophs, allowing researchers to explore synergistic cellular signaling within controlled experimental models.
From a molecular research perspective, the CJC/Ipamorelin combination provides a valuable model for investigating the dynamics of receptor co-activation and signal transduction crosstalk. In biological systems, the somatotropic axis is regulated by the balance of Growth Hormone-Releasing Hormone (GHRH), which stimulates release, and Somatostatin, which inhibits it. GHRH agonists like CJC-1295 increase somatotroph intracellular cAMP levels. Simultaneously, GHSR agonists like Ipamorelin act to increase intracellular calcium mobilization via the phospholipase C (PLC) pathway and attenuate somatostatin's inhibitory tone. By evaluating this combined exposure, researchers can study synergistic signal amplification at the somatotroph membrane.
Current laboratory investigations examine the intracellular cascades initiated by combined GHRHR and GHSR activation. Studies focus on the rapid accumulation of cyclic adenosine monophosphate (cAMP), the activation of protein kinase A (PKA), the formation of inositol trisphosphate (IP3), and the subsequent mobilization of intracellular calcium stores. This dual activation leads to vesicle docking and pulsatile growth hormone degranulation, allowing researchers to analyze endocrine secretion dynamics under controlled in vitro conditions.
Beyond pituitary receptor mechanics, researchers use the CJC/Ipamorelin blend to explore downstream somatotrophic axis regulation. Studies evaluate how growth hormone release stimulated by GHRH and GHSR co-activation coordinates hepatic insulin-like growth factor 1 (IGF-1) synthesis and release. This feedback loop is studied to analyze receptor sensitivity, cellular signaling thresholds, and homeostatic endocrine feedback mechanisms under synergistic exposure.
The liquid spray formulation provides an optimized experimental vehicle for investigating non-invasive mucosal epithelial transport. Researchers analyze how the combined 29-amino-acid peptide and 5-amino-acid pentapeptide cross nasal or oral mucosal barriers, evaluating tight junction interactions and trans-epithelial transport rates of peptide blends. Additionally, in neurobiology, the intranasal spray format is investigated to study direct olfactory transport pathways bypass of the blood-brain barrier for CNS-somatotrophic axis studies.
Each bottle of CJC/Ipamorelin 5/5mg spray is manufactured using solid-phase peptide synthesis (SPPS) for both individual peptides, followed by purification and precise ratio blending. The peptides are then dissolved in a stabilized, buffered aqueous solution calibrated to ensure exact concentration of 5mg CJC-1295 No DAC and 5mg Ipamorelin per bottle. Quality control protocols include reverse-phase high-performance liquid chromatography (HPLC) for purity verification of both active ingredients and liquid chromatography-mass spectrometry (LC-MS) for molecular identity confirmation.
To preserve the stability of both peptides in solution, CJC/Ipamorelin Spray should be stored under refrigeration (2°C to 8°C) and protected from light. Because GHRH and GHSR analogs can undergo oxidation, deamidation, or hydrolysis in aqueous environments over time, maintaining refrigerated storage and minimizing atmospheric exposure is critical to preserving peptide integrity. Proper handling supports consistent concentration and analytical reproducibility across laboratory protocols.
Scientific interest in the CJC/Ipamorelin blend continues to expand as researchers seek to characterize its stability, synergistic receptor interactions, and transport kinetics. Nevertheless, many aspects of its cellular signaling and epithelial transport remain active areas of scientific inquiry. Ongoing studies continue to refine the understanding of peptide blend behavior in biological systems. For this reason, CJC/Ipamorelin 5/5mg spray should be regarded as an investigational compound whose primary value lies in advancing scientific knowledge of somatotropic receptor biology.
CJC/Ipamorelin 5/5mg Spray is supplied exclusively for laboratory research and analytical applications. It is intended for Research Use Only (RUO) and is not approved for human consumption, therapeutic use, veterinary use, or diagnostic purposes.
Telomerase enzyme explained: how TERT and TERC maintain telomeres, why it matters in aging and cancer research, plus RUO peptide sourcing. Read the guide.
KLOW peptide research blend is drawing attention across California's research community. Discover its composition, COA basics, and current evidence limits.
Learn what a peptide bond is, how it forms through dehydration synthesis, and why its structure matters for research peptides. Read the full guide now.
(faqs)
